Drugs known as GLP‑1 receptor agonists have become very popular in recent years. These medicines are widely used to treat type 2 diabetes and, more recently, to help people lose weight.
Well‑known examples include semaglutide, liraglutide, dulaglutide, and exenatide. Some of these drugs are sold under well‑known brand names that have received enormous attention because of their effectiveness for weight loss.
These medicines work by copying the action of a natural hormone in the body called glucagon‑like peptide‑1, or GLP‑1. This hormone helps control blood sugar levels, slows down digestion, and reduces appetite.
Because of these effects, GLP‑1 drugs can help people with diabetes manage their blood sugar and can also help many people lose significant amounts of weight.
However, as millions of people begin using these medications, researchers are starting to examine their long‑term health effects more closely. A new study suggests that people who take these drugs may face a slightly higher risk of certain bone and joint conditions.
The research was presented at the annual meeting of the American Academy of Orthopaedic Surgeons, which took place from March 2 to March 6 in New Orleans. The study was led by Muaaz Wajahath from the Michigan State University College of Human Medicine.
The researchers wanted to understand whether long‑term use of GLP‑1 medications might affect bone and joint health. They focused on three conditions: osteoporosis, gout, and osteomalacia.
Osteoporosis is a disease in which bones become weak and fragile. When bones lose strength, they are more likely to break even after minor falls or injuries. Osteoporosis is already common in older adults, especially women.
Gout is a form of arthritis caused by the buildup of uric acid crystals in the joints. These crystals can cause sudden and extremely painful swelling, most often in the big toe but sometimes in other joints.
Osteomalacia is a condition that causes bones to become soft because they do not harden properly. It is usually linked to problems with vitamin D or mineral metabolism and can lead to bone pain and muscle weakness.
To investigate the possible connection between GLP‑1 drugs and these conditions, the research team analyzed medical data from a very large group of adults who had both type 2 diabetes and obesity.
The study included more than 146,000 people in total. About half of the participants, 73,483 individuals, had been treated with GLP‑1 medications. The researchers compared them with another group of the same size who did not use these drugs but had similar health conditions.
The scientists then followed the health outcomes of these patients over a five‑year period. By comparing the two groups, they were able to estimate whether people taking GLP‑1 drugs had different risks for developing bone or joint problems.
The results showed that several conditions occurred more often in the group using GLP‑1 medications.
After five years, about 4.1 percent of people taking GLP‑1 drugs developed osteoporosis. In comparison, about 3.2 percent of people in the control group developed the disease. This represents a relative risk increase of about 29 percent.
The researchers also observed a higher rate of gout among people using GLP‑1 medications. About 7.4 percent of GLP‑1 users developed gout over five years, compared with 6.6 percent of people who did not take the drugs.
The largest relative difference appeared in osteomalacia. Although this condition remained rare overall, about 0.2 percent of GLP‑1 users developed it, compared with 0.1 percent of people in the comparison group. This represents a relative risk that was more than twice as high.
According to the researchers, the differences between the two groups were statistically significant. This means the results were unlikely to be explained by chance alone.
However, the scientists emphasized that the absolute risks remain relatively small. For example, the increase in osteoporosis risk was less than one percentage point over five years.
Wajahath explained that scientists are only now beginning to gather long‑term data about these medications. GLP‑1 drugs have been adopted very quickly in medical practice, especially because of their effectiveness for weight loss.
Because of this rapid growth in use, researchers believe it is important to monitor possible long‑term side effects carefully.
This is especially relevant in orthopedic medicine, where doctors often treat bone and joint problems in patients who also have obesity or diabetes. These patients may already face higher risks of bone disease or arthritis.
When reviewing the study’s findings, it is important to understand both the strengths and the limitations of the research.
One strength of the study is its very large sample size. By examining data from more than 140,000 people, the researchers were able to detect patterns that smaller studies might miss.
However, the study does not prove that GLP‑1 medications directly cause these bone and joint conditions. It only shows an association between drug use and higher rates of these problems.
Other factors may also contribute to the increased risks. For example, people with obesity and diabetes may already have metabolic changes that affect bone health, vitamin levels, or uric acid metabolism.
Another important point is that the increased risks were relatively modest. For many patients, the benefits of GLP‑1 medications, such as improved blood sugar control and weight loss, may still outweigh the potential risks.
Nevertheless, the findings suggest that doctors and researchers should continue studying the long‑term effects of these drugs. Monitoring bone health, nutrition, and mineral levels may become more important for people who take GLP‑1 medications for many years.
As longer follow‑up studies become available, scientists will gain a clearer understanding of how these medications influence bone and joint health over time.
For now, the study highlights the importance of careful monitoring as new treatments become widely used. While GLP‑1 medications offer major benefits for diabetes and obesity management, continued research will help ensure that their long‑term safety is fully understood.
If you care about weight loss, please read studies about orange that could help obesity, and a berry that can prevent cancer, diabetes and obesity.
For more health information, please see recent studies about ginger’s journey in weight management, and green tea: a cup of weight loss.
Copyright © 2026 Knowridge Science Report. All rights reserved.
